Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Ann Hematol ; 100(4): 891-901, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33388858

ABSTRACT

Curcuminoids, polyphenol compounds in turmeric, possess several pharmacological properties including antioxidant, iron-chelating, and anti-inflammatory activities. Effects of curcuminoids in thalassemia patients have been explored in a limited number of studies using different doses of curcuminoids. The present study aims to evaluate the effects of 24-week curcuminoids supplementation at the dosage of 500 and 1000 mg/day on iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfused ß-thalassemia/Hb E patients. In general, both curcuminoids dosages significantly lowered the levels of oxidative stress, hypercoagulability, and inflammatory markers in the patients. In contrast, reductions in iron parameter levels were more remarkable in the 1000 mg/day group. Subgroup analysis revealed that a marker of hypercoagulability was significantly decreased only in patients with baseline ferritin ≤ 1000 ng/ml independently of curcuminoids dosage. Moreover, the alleviation of iron loading parameters was more remarkable in patients with baseline ferritin > 1000 ng/ml who receive 1000 mg/day curcuminoids. On the other hand, the responses of oxidative stress markers were higher with 500 mg/day curcuminoids regardless of baseline ferritin levels. Our study suggests that baseline ferritin levels should be considered in the supplementation of curcuminoids and the appropriate curcuminoids dosage might differ according to the required therapeutic effect. Thai Clinical Trials Registry (TCTR): TCTR20200731003; July 31, 2020 "retrospectively registered".


Subject(s)
Diarylheptanoids/therapeutic use , Dietary Supplements , Hemoglobin E/genetics , Hemoglobinopathies/drug therapy , Inflammation/drug therapy , Iron Overload/drug therapy , Thrombophilia/drug therapy , Adolescent , Adult , Biomarkers , Blood Proteins/analysis , Cytokines/blood , Diarylheptanoids/administration & dosage , Diarylheptanoids/pharmacology , Dose-Response Relationship, Drug , Female , Ferritins/blood , Hemoglobinopathies/blood , Hemoglobinopathies/complications , Hemoglobinopathies/genetics , Heterozygote , Humans , Inflammation/blood , Inflammation/etiology , Iron Overload/etiology , Male , Malondialdehyde/blood , Middle Aged , Oxidative Stress/drug effects , Reactive Oxygen Species/blood , Retrospective Studies , Thrombophilia/blood , Thrombophilia/etiology , Young Adult , beta-Globins/genetics , beta-Thalassemia/blood , beta-Thalassemia/complications , beta-Thalassemia/drug therapy , beta-Thalassemia/genetics
2.
ScientificWorldJournal ; 2013: 543973, 2013.
Article in English | MEDLINE | ID: mdl-24223032

ABSTRACT

ß -thalassemia/Hb E is known to cause oxidative stress induced by iron overload. The glutathione system is the major endogenous antioxidant that protects animal cells from oxidative damage. This study aimed to determine the effect of disease state and splenectomy on redox status expressed by whole blood glutathione (GSH)/glutathione disulfide (GSSG) and also to evaluate glutathione-related responses to oxidation in ß -thalassemia/Hb E patients. Twenty-seven normal subjects and 25 ß -thalassemia/Hb E patients were recruited and blood was collected. The GSH/GSSG ratio, activities of glutathione-related enzymes, hematological parameters, and serum ferritin levels were determined in individuals. Patients had high iron-induced oxidative stress, shown as significantly increased serum ferritin, a decreased GSH/GSSG ratio, and increased activities of glutathione-related enzymes. Splenectomy increased serum ferritin levels and decreased GSH levels concomitant with unchanged glutathione-related enzyme activities. The redox ratio had a positive correlation with hemoglobin levels and negative correlation with levels of serum ferritin. The glutathione system may be the body's first-line defense used against oxidative stress and to maintain redox homeostasis in thalassemic patients based on the significant correlations between the GSH/GSSH ratio and degree of anemia or body iron stores.


Subject(s)
Glutathione Disulfide/blood , Glutathione/blood , Oxidation-Reduction , beta-Thalassemia/blood , Case-Control Studies , Female , Ferritins/blood , Hemoglobin E/analysis , Humans , Male , Splenectomy , beta-Thalassemia/metabolism , beta-Thalassemia/surgery
3.
Hematology ; 24(1): 300-307, 2019 Dec.
Article in English | MEDLINE | ID: mdl-30661467

ABSTRACT

OBJECTIVE: Iron overload and oxidative stress are the major causes of serious complications and mortality in thalassemic patients. Our previous work supports the synergistic effects of antioxidant cocktails (curcuminoids or vitamin E, N-acetylcysteine, and deferiprone) in treatment of ß-thalassemia/Hb E patients. This further 2-DE-based proteomic study aimed to identify the plasma proteins that expressed differentially in response to antioxidant cocktails. METHODS: Frozen plasma samples of ten normal subjects and ten ß-thalassemia/Hb E patients at three-time points (baseline, month 6, and month 12) were reduced the dynamic range of proteome using ProteoMiner kit and separated proteins by two-dimensional gel electrophoresis. Differentially expressed proteins were identified using tandem mass spectrometry. Several plasma proteins were validated by ELISA and Western blot analysis. RESULTS: Thirteen and 11 proteins were identified with altered expression levels in the curcuminoids- and vitamin E cocktail groups, respectively. The associations between vitronectin (VTN) expression and total bilirubin levels, as well as between serum paraoxonase/arylesterase 1 (PON1) expression and blood reactive oxygen species were observed. Validation results were consistent with proteomics results. DISCUSSION AND CONCLUSIONS: These plasma proteins may provide better understanding of the mechanisms underlying the therapeutic effects of antioxidant cocktails in thalassemic patients.


Subject(s)
Acetylcysteine/administration & dosage , Blood Proteins/biosynthesis , Curcumin , Deferiprone/administration & dosage , Free Radical Scavengers/administration & dosage , Gene Expression Regulation/drug effects , Hemoglobin E , Vitamin E/administration & dosage , beta-Thalassemia , Adult , Curcumin/administration & dosage , Curcumin/analogs & derivatives , Drug Therapy, Combination , Female , Humans , Male , beta-Thalassemia/blood , beta-Thalassemia/drug therapy
4.
Oxid Med Cell Longev ; 2015: 537954, 2015.
Article in English | MEDLINE | ID: mdl-26078808

ABSTRACT

Studies on the antioxidant treatment for thalassemia have reported variable outcomes. However, treatment of thalassemia with a combination of hydrophobic and hydrophilic antioxidants and an iron chelator has not been studied. This study investigated the effects of antioxidant cocktails for the treatment of ß-thalassemia/hemoglobin E (HbE), which is the most common form of ß-thalassemia in Southeast Asia. Sixty patients were divided into two groups receiving N-acetylcysteine, deferiprone, and either curcuminoids (CUR) or vitamin E (Vit-E), and their hematological parameters, iron load, oxidative stress, and blood coagulation potential were evaluated. Patients were classified as responders if they showed the improvements of the markers of iron load and oxidative stress, otherwise as nonresponders. During treatment, the responders in both groups had significantly decreased iron load, oxidative stress, and coagulation potential and significantly increased antioxidant capacity and hemoglobin concentration. The significantly maximum increase (P < 0.01) in hemoglobin concentration was 11% at month 4 in CUR group responders and 10% at month 10 in Vit-E group responders. In conclusion, the two antioxidant cocktails can improve anemia, iron overload, oxidative stress, and hypercoagulable state in ß-thalassemia/HbE.


Subject(s)
Antioxidants/therapeutic use , Hemoglobin E/metabolism , beta-Thalassemia/drug therapy , Adult , Antioxidants/pharmacology , Aspartate Aminotransferases/metabolism , Bilirubin , Blood Coagulation/drug effects , Female , Ferritins/blood , Glutathione/metabolism , Hemoglobins/analysis , Humans , Iron Overload/pathology , Iron Overload/prevention & control , Male , Oxidative Stress/drug effects , Platelet Activation/drug effects , Reactive Oxygen Species/metabolism , Superoxide Dismutase/metabolism , beta-Thalassemia/metabolism , beta-Thalassemia/pathology
5.
J Nutr Biochem ; 24(3): 578-85, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22818714

ABSTRACT

Thalassemic patients often exhibit high levels of oxidative stress and iron overload, which can lead to hazardous complications. Curcuminoids, extracted from the spice turmeric, are known to have antioxidant and iron-chelating properties and have been proposed as a potential upstream therapy of thalassemia. Here we have applied proteomic techniques to study the protein profile and oxidative damage in the plasma of ß-thalassemia/Hb E patients before and after treatment with curcuminoids. In this study, 10 ß-thalassemia/Hb E patients were treated with 500 mg curcuminoids daily for 12 months. The plasma protein profile and protein carbonyl content were determined at baseline, 6 and 12 months using two-dimensional fluorescence difference gel electrophoresis and carbonyl immunoblotting, respectively. Other hematological, clinical, and biochemical parameters were also analyzed. Twenty-six spots, identified as coagulation factors and proteins involved in iron homeostasis, showed significantly decreased intensity in thalassemic plasma, compared to those of normal subjects. Treatment with curcuminoids up-regulated the plasma levels of these proteins and reduced their oxidative damage. Serum non-transferrin bound iron, platelet factor-3 like activity, oxidative stress parameters and antioxidant enzymes were also improved after curcuminoids treatment. This study is the first proteomic study of plasma in the thalassemic state and also shows the ameliorating role of curcuminoids towards oxidative stress and iron overload in the plasma proteome.


Subject(s)
Dietary Supplements , Oxidative Stress/drug effects , Plant Extracts/pharmacokinetics , Proteome/analysis , beta-Thalassemia/drug therapy , Adult , Antioxidants/pharmacology , Curcuma/chemistry , Female , Hemoglobin E , Humans , Iron Chelating Agents/chemistry , Iron Overload/drug therapy , Male , Middle Aged , Protein Carbonylation , Proteomics/methods , Transferrin/analysis , Transferrin/metabolism , Up-Regulation , Young Adult
6.
Clin Biochem ; 43(4-5): 424-9, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19900435

ABSTRACT

OBJECTIVES: To evaluate the hematological profile, oxidative stress, and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids for 12 months. DESIGN AND METHODS: Twenty-one beta-thalassemia/Hb E patients were given 2 capsules of 250 mg each of curcuminoids (a total of 500 mg) daily for 12 months. Blood was collected every 2 months during treatment and 3 months after withdrawal and was determined for complete blood count, malonyldialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), reduced glutathione (GSH) in red blood cells (RBC), and non-transferrin bound iron (NTBI) in serum. RESULTS: The increased oxidative stress in beta-thalassemia/Hb E patients was shown by higher levels of MDA, SOD, GSH-Px in RBC, serum NTBI, and lower level of RBC GSH. Curcuminoids administration resulted in improvement of all the measured parameters as long as they were administered. After 3 months withdrawal of treatment, all parameters returned close to baseline levels. CONCLUSION: Curcuminoids may be used to ameliorate oxidative damage in patients with beta-thalassemia/Hb E disease.


Subject(s)
Antioxidants/metabolism , Curcumin/pharmacology , Curcumin/therapeutic use , Enzyme Inhibitors/therapeutic use , Hemoglobin E/metabolism , Oxidative Stress/drug effects , beta-Thalassemia/drug therapy , Adolescent , Adult , Enzyme Inhibitors/pharmacology , Female , Glutathione/blood , Glutathione Peroxidase/blood , Humans , Male , Malondialdehyde/blood , Middle Aged , Superoxide Dismutase/blood , Young Adult , beta-Thalassemia/blood
SELECTION OF CITATIONS
SEARCH DETAIL